Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)
China · Delayed Price · Currency is CNY 8.21
-0.17 (-2.03%)
May 12, 2026, 3:04 PM CST
SHE:002566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 657.45 | 637.96 | 665.38 | 850.63 | 829.06 | 875.14 |
Other Revenue | 2.21 | 2.21 | 3.09 | 3.03 | 0.98 | 2.79 |
| 659.66 | 640.17 | 668.47 | 853.66 | 830.04 | 877.93 | |
Revenue Growth (YoY) | 5.17% | -4.23% | -21.69% | 2.85% | -5.46% | 4.19% |
Cost of Revenue | 175.23 | 170.49 | 174.13 | 224.8 | 215.44 | 221.22 |
Gross Profit | 484.43 | 469.69 | 494.34 | 628.87 | 614.6 | 656.71 |
Selling, General & Admin | 433.74 | 415.6 | 428.17 | 509.94 | 489.33 | 506.34 |
Research & Development | 15.79 | 15.14 | 16.22 | 18.68 | 18.78 | 20.89 |
Other Operating Expenses | 10.43 | 14.66 | -6.74 | -6.62 | 16.5 | 15.96 |
Operating Expenses | 462.08 | 447.53 | 437.42 | 522 | 525.88 | 542.74 |
Operating Income | 22.35 | 22.16 | 56.92 | 106.86 | 88.73 | 113.97 |
Interest Expense | -12.62 | -12.62 | -13.84 | -13.66 | -14.03 | -13.36 |
Interest & Investment Income | 16.9 | 13.81 | 11.69 | 16.31 | 11.14 | 9.27 |
Currency Exchange Gain (Loss) | 0 | 0 | -0 | - | -0 | - |
Other Non Operating Income (Expenses) | -1.62 | -0.75 | -1.96 | -0.68 | -1.92 | 0.13 |
EBT Excluding Unusual Items | 25.01 | 22.61 | 52.82 | 108.83 | 83.91 | 110.01 |
Gain (Loss) on Sale of Investments | -1.7 | -3.82 | 6.69 | 2.39 | -0.32 | 0.16 |
Gain (Loss) on Sale of Assets | 0.47 | 0.4 | 0.29 | 0.78 | - | - |
Asset Writedown | -0.3 | -0.3 | -0.27 | -0.24 | -0.27 | -0.28 |
Other Unusual Items | 11.18 | 11.18 | 0.02 | 0 | 17.9 | 13.48 |
Pretax Income | 34.66 | 30.06 | 59.55 | 111.76 | 101.23 | 123.37 |
Income Tax Expense | 1.54 | 1.13 | 8.89 | 15.65 | 12.91 | 18.67 |
Earnings From Continuing Operations | 33.12 | 28.93 | 50.66 | 96.11 | 88.32 | 104.7 |
Minority Interest in Earnings | 0.17 | 0.07 | 1.43 | -1.38 | -5.22 | -8.68 |
Net Income | 33.28 | 29 | 52.09 | 94.73 | 83.1 | 96.02 |
Net Income to Common | 33.28 | 29 | 52.09 | 94.73 | 83.1 | 96.02 |
Net Income Growth | -22.48% | -44.32% | -45.02% | 14.00% | -13.46% | 19.93% |
Shares Outstanding (Basic) | 331 | 331 | 331 | 331 | 331 | 331 |
Shares Outstanding (Diluted) | 331 | 331 | 331 | 331 | 331 | 331 |
Shares Change (YoY) | -0.03% | 0.04% | -0.03% | 0.02% | -0.02% | 0.01% |
EPS (Basic) | 0.10 | 0.09 | 0.16 | 0.29 | 0.25 | 0.29 |
EPS (Diluted) | 0.10 | 0.09 | 0.16 | 0.29 | 0.25 | 0.29 |
EPS Growth | -22.45% | -44.35% | -45.00% | 13.98% | -13.44% | 19.93% |
Free Cash Flow | 100.89 | 85.1 | 43 | 173.36 | 104.49 | 108.04 |
Free Cash Flow Per Share | 0.30 | 0.26 | 0.13 | 0.52 | 0.32 | 0.33 |
Dividend Per Share | 0.080 | 0.080 | 0.100 | 0.150 | 0.050 | 0.030 |
Dividend Growth | -20.00% | -20.00% | -33.33% | 200.00% | 66.67% | - |
Gross Margin | 73.44% | 73.37% | 73.95% | 73.67% | 74.05% | 74.80% |
Operating Margin | 3.39% | 3.46% | 8.52% | 12.52% | 10.69% | 12.98% |
Profit Margin | 5.04% | 4.53% | 7.79% | 11.10% | 10.01% | 10.94% |
Free Cash Flow Margin | 15.29% | 13.29% | 6.43% | 20.31% | 12.59% | 12.31% |
EBITDA | 59.79 | 60.66 | 99.68 | 152.08 | 128.82 | 154.25 |
EBITDA Margin | 9.06% | 9.48% | 14.91% | 17.82% | 15.52% | 17.57% |
D&A For EBITDA | 37.44 | 38.5 | 42.76 | 45.21 | 40.09 | 40.28 |
EBIT | 22.35 | 22.16 | 56.92 | 106.86 | 88.73 | 113.97 |
EBIT Margin | 3.39% | 3.46% | 8.52% | 12.52% | 10.69% | 12.98% |
Effective Tax Rate | 4.45% | 3.76% | 14.93% | 14.00% | 12.75% | 15.14% |
Revenue as Reported | 640.17 | 640.17 | 668.47 | 853.66 | 830.04 | 877.93 |
Advertising Expenses | - | 4.27 | 6.21 | 6.7 | 4.4 | 7.97 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.